7 completed, 1 recruiting, 1 terminated, 1 withdrawn. 8 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 5, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 5 | Completed 2, Recruiting 1, Terminated 1, Withdrawn 1 |
Follow Squamous Cell Carcinoma of the Esophagus: new trials by email Literature Review of Squamous Cell Carcinoma of the Esophagus trials Research Report on Squamous Cell Carcinoma of the Esophagus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of IDP-001 in Advanced or Metastatic Solid Tumors IDP-001 - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 / Phase 2 | Recruiting | InduPro, Inc. | 132 | 2026-07-08 | 2026-09-03 |
| A Study of KF-0210 in Advanced Solid Tumors Patients KF-0210 tablets, 120 mg, KF-0210 tablets, 240 mg, KF-0210 tablets, 450 mg - Advanced Solid Tumor, Colorectal Cancer | Phase 1 | Completed | Keythera Pharmaceuticals (Australia) Pty Ltd | 14 | 2021-03-09 | 2024-09-24 |
| Study With Paclitaxel +/- Ramucirumab in Patients With Squamous-cell Carcinoma of the Esophagus After Prior Therapy Ramucirumab, Paclitaxel - Squamous Cell Carcinoma of the Esophagus | Phase 2 | Completed | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 21 | 2019-03-08 | 2022-12-08 |
| Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA Monalizumab, Oxaliplatin, 5-Fluorouracil - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 1 / Phase 2 | Withdrawn | Jules Bordet Institute | 2017-07-20 | 2017-12-19 | |
| Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery cyclodextrin-based polymer-camptothecin CRLX101, Laboratory biomarker analysis, Pharmacological studies - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 2 | Completed | City of Hope Medical Center | 10 | 2012-11-01 | 2018-02-01 |
| Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer bevacizumab, oxaliplatin, leucovorin calcium - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 2 | Completed | Fox Chase Cancer Center | 20 | 2011-04-27 | 2022-09-07 |
| Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy pralatrexate, docetaxel, fludeoxyglucose F 18 - Adenocarcinoma of the Esophagus, Adenocarcinomas of the Gastroesophageal Junction | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 6 | 2010-07-01 | 2016-06-01 |
| Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction erlotinib hydrochloride, oxaliplatin, fluorouracil - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 1 | Completed | Wake Forest University Health Sciences | 9 | 2007-04-01 | 2018-07-02 |
| A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer oblimersen sodium, cisplatin, fluorouracil - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 15 | 2003-06-01 | 2021-02-17 |
| Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer erlotinib hydrochloride, laboratory biomarker analysis - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 2 | Completed | National Cancer Institute (NCI) | 48 | 2002-06-01 | 2013-06-04 |
Esophageal Squamous Cell Carcinoma (10) · Adenocarcinoma Of Esophagus (7) · Esophageal Neoplasms (6) · Stomach Neoplasms (5) · Adenocarcinoma (1) · Anus Neoplasms (1) · Carcinoma, Squamous Cell (1) · Colorectal Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Squamous Cell Carcinoma of Head and Neck (1) · Urinary Bladder Neoplasms (1)
Carcinoma (10) · Digestive System Diseases (10) · Digestive System Neoplasms (10) · Esophageal Diseases (10) · Gastrointestinal Diseases (10) · Gastrointestinal Neoplasms (10) · Head and Neck Neoplasms (10) · Neoplasms (10) · Neoplasms by Histologic Type (10) · Neoplasms by Site (10) · Neoplasms, Glandular and Epithelial (10) · Neoplasms, Squamous Cell (10) · Carcinoma, Squamous Cell (9) · Stomach Diseases (5) · Esophageal Neoplasms (4)
Fluorouracil (4) · Oxaliplatin (3) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (2) · Erlotinib Hydrochloride (2) · Fluorodeoxyglucose F18 (2) · Magnetic Resonance Spectroscopy (2) · Surgical Procedures, Operative (2) · 10-propargyl-10-deazaaminopterin (1) · Bevacizumab (1) · Cisplatin (1) · Congresses as Topic (1) · Docetaxel (1) · Gene Expression Profiling (1) · IT-101 (1) · Immunohistochemistry (1)
National Cancer Institute (NCI) (2) · City of Hope Medical Center (1) · Fox Chase Cancer Center (1) · InduPro, Inc. (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · Jules Bordet Institute (1) · Keythera Pharmaceuticals (Australia) Pty Ltd (1) · Ohio State University Comprehensive Cancer Center (1) · Wake Forest University Health Sciences (1)
United States (7) · Australia (1) · Belgium (1) · Germany (1)
Amelie Deleporte, Physician (1) · Andreas Kaubisch (1) · Arthur Blackstock (1) · Crystal Denlinger (1) · David Ilson (1) · Joseph Chao (1) · Rasha Cosman, MD (1) · Salah-Eddin Al-Batran, Prof. Dr. (1) · Tony Saab, MD (1)
2016 (2), N01CM62204 (1), N01CM62206 (1), P30CA006927 (1)